Fig. 8

MiR-138-1-3p sensitized sorafenib to HCC by targeting PAK5 in vivo. A At 27 days post-inoculation, mice were killed and B tumor weights were measured. C The tumor volumes were monitored every 7 days. D Representative images of PAK5 and ABCB1 immunohistochemical staining with PAK5 and ABCB1 antibodies in four groups as shown. E The schematic diagram displayed that MicroRNA-138-1-3p sensitized sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway